REFERENCES
- Yao Y F, Zhang Y M, Zhou P, et al. Therapeutic penetrating keratoplasty in severe fungal keratitis using cryopreserved donor corneas. Br J Ophthalmol 2003; 87: 543–547, [PUBMED], [INFOTRIEVE], [CSA]
- Davise H L. Medically Important Fungi: A Guide to Identification. 4th ed. ASM Press, Washington, DC 2002; 304–305
- Thomas P A. Mycotic keratitis—an underestimated mycosis. J Med Vet Mycol 1994; 32: 235–256, [PUBMED], [INFOTRIEVE], [CSA]
- Thomas P A. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003; 16: 730–797, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rex J H, Pfaller M A. Has antifungal susceptibility testing come of age. Clin Infect Dis 2002; 35: 982–989, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Second edition. NCCLS document M27-A2, Wayne, PAUSA 2002
- National Committee for Clinical and Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard. NCCLS document M38-A. Wayne, PAUSA 2002
- Rex J H, Pfaller M A, Walsh T J, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Leck A K, Thomas P A, Hagan M, et al. Etiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol 2002; 86: 1211–1215, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tanure M A, Cohen E J, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 2000; 19: 307–312, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39: 1360–1367, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pfaller M A, Messer S A, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38: 3359–3361, [PUBMED], [INFOTRIEVE], [CSA]
- Inoue T, Inoue Y, Asari S, et al. Utility of Etest in choosing appropriate agents to treat fungal keratitis. Cornea 2001; 20: 607–609, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39: 163–167, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fridkin S K, Jarvis W R. Epidemiology of nosocomial fungal infection. Clin Microbiol Rev 1996; 9: 499–511, [PUBMED], [INFOTRIEVE], [CSA]
- Szekely A, Johnson E M, Warnock D W. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37: 1480–1483, [PUBMED], [INFOTRIEVE], [CSA]
- Pfaller M A, Messer S A, Hollis R J, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032–1037, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Espinel-Ingroff A. Clinical relevance of fungal susceptibility testing and antifungal resistance. Clin Microbiol News 2000; 22: 137–140, [CSA], [CROSSREF]